Formation of de novo donor-specific antibodies (dn-DSas) has been associated with longterm immunologic complications after liver transplantation (lt). We hypothesized that human leukocyte antigen (Hla) epitope/eplet mismatch (MM) is a marker of immunogenicity and a risk factor for dn-DSa formation. Sera from 80 lt recipients were prospectively screened for dn-DSa by a luminex single-antigen test (One lambda, inc., canoga Park, ca) at 1, 2, 3, 6, 12, 18, 24, and 36 months after lt. Hla typing of the recipients and donors was performed using polymerase chain reaction (Pcr)-SSP and Pcr-SSOP luminex low-resolution methods (One lambda, inc.). the HlaMatchmaker computer algorithm was used for identification of MM eplets at Hla-DrB1 and -DQa1/B1 loci. luminex single-antigen bead solid phase assay was used for antibody analysis. Standard immunosuppression included thymoglobulin-rituximab induction and tacrolimus maintenance. there were 27 (34%) patients who developed dn-DSa. there were no episodes of antibody-mediated rejection, and 9 (11%) developed acute cellular rejection (acr). a positive crossmatch status and a higher number of Hla-a, -B, -Dr, and -aBDr MMs were not associated with dn-DSa formation. Patients developing dn-DSa had a significantly higher number of total (38 ± 2.7 versus 28 ± 2.3; P = 0.01) and antibody-verified (abVer; 14 ± 1.1 versus 10 ± 1; P = 0.015) class ii MM eplets. By a multivariate regression analysis, the number of class ii MM eplets was strongly associated with risk of class ii dn-DSa formation (odds ratio [Or], 1.2; P < 0.01). Patients with acr had a significantly higher number of total (20.2 ± 1.3 versus 13.9 ± 0.9; P < 0.01) as well as abVer (10.7 ± 1.1 versus 7.5 ± 0.6; P = 0.03) class i MM eplets. in conclusion, donor-recipient Hla epitope MM is associated with a risk of dn-DSa formation and rejection after lt. However, further studies are required to evaluate the clinical utility of epitope matching in lt.
The adverse impact of human leukocyte antigen (HLA) donor-specific antibodies (DSAs) in liver transplantation (LT) recipients is already established. (1) (2) (3) Many studies have demonstrated associations between de novo donor-specific antibody (dn-DSA) with liver allograft injury. (3, 4) Protocol liver biopsies from pediatric recipients have shown a gradual development of allograft fibrosis in association with anti-class II DSA. (5, 6) Although deleterious effects of dn-DSA have been demonstrated, there are sparse data on the risk factors for developing dn-DSA in the setting of LT. Kaneku et al. have shown that patients receiving weaker immunosuppression and with DQ mismatch (MM) are at an increased risk of dn-DSA formation. (7) Whether pretransplant immunologic parameters such as HLA MM and crossmatch (CM) status influence dn-DSA formation is unknown. Identifying risk factors responsible for development of dn-DSA and strategies to mitigate dn-DSA-led injury may improve outcomes after LT.
In kidney transplantation, the degree of HLA MM has been associated with the formation of DSA and rejection, which has led to kidney allocation based on HLA matching. (8) However, we now know that DSA bind to specific epitopes on the antigen surface and not to the entire HLA antigen. Anti-HLA antibodies recognize epitopes, which can be structurally defined by eplets, which are small configurations of polymorphic amino acids on the HLA molecular surface. The recent advances based on an understanding of molecular models of HLA epitope structures and their reactivity with antibodies have led to donor-recipient matching at the epitope level instead of by HLAs. Epitope-based matching has already shown improvement of outcomes in other organs. (9) (10) (11) (12) (13) (14) Some studies have shown that HLA class I and class II MMs with low eplet loads are less likely to induce antibody responses. (15) Recently, Willicombe et al. demonstrated that the epitope MM burden predicts the risk of dn-DSA formation in kidney transplantation. (16) Although epitope-matching-based allocation is not practical in LT, the risk of dn-DSA formation and/ or immunologic outcomes can be stratified using this approach to select high-risk patients for closer surveillance or potent immunosuppression and those with a low risk for tolerance protocols. (17) To our knowledge, no previous study has systemically analyzed the impact of epitope MM on DSA formation in the setting of LT. We hypothesized that a higher degree of epitope MM at class II HLA is a predictor of dn-DSA formation. To test this hypothesis, we used HLAMatchmaker, a computer algorithm that determines HLA matching at the epitope level.
Patients and Methods

STUDY popULaTIoN
Between January 2010 and October 2011, 92 adult LT recipients were prospectively enrolled in this study. Approval for the study was obtained from the institutional review board at the Indiana University School of Medicine. All patients received induction immunosuppression in the form of rabbit antithymocyte globulin (3 doses of 2 mg/kg) and rituximab (single dose of 150 mg/m 2 body surface area) with a methylprednisolone taper. The maintenance immunosuppression was tacrolimus monotherapy. Target trough tacrolimus levels between 8 and 10 ng/dL were maintained for the first 3 months and then decreased to 6-8 ng/dL, thereafter. Protocol liver biopsies were performed in patients with hepatitis C virus (HCV) for staging HCV recurrence. Additionally, liver biopsies were performed to evaluate graft function with abnormal liver function tests. Acute cellular rejection (ACR) episodes were treated with methylprednisolone pulse with or without thymoglobulin.
CM aND aNaLYSIS oF DSa
A positive flow cytometry crossmatch (FCCM) was defined as a shift in the mean channel of fluorescence of more than 50 channels to the right for the T cell peak and more than 150 channels for the B cell peak in the test sera compared with the negative control. A positive result due to non-DSA was considered as a negative CM. Transplants were performed regardless of CM status. The prospective monitoring included screening of sera for DSA by Luminex single-antigen test (One Lambda, Inc., Canoga Park, CA) at 1, 2, 3, 6, 12, 18, 24, and 36 months after transplant. Twelve patients with inadequate follow-up were excluded from the analysis. DSA with mean fluorescence intensity (MFI) > 3000 were considered significant. (18) HLA-A, -B, -C, -DRB1, 3, 4, 5, and -DQA/B typing of the recipients and donors was performed using polymerase chain reaction (PCR)-SSP (Qiagen, Inc., Valencia, CA) and PCR-SSOP Luminex low-resolution (One Lambda, Inc.) methods. All of the tests were performed according to the manufacturer's instructions. Anti-HLA antibodies of the immunoglobulin G isotype against HLA-A, -B, -C, -DRB, and -DQ were tested using single-antigen bead Luminex technology (Lab screen Single Antigen; One Lambda, Inc.). The HLAMatchmaker computer algorithm was used for the identification of MM epitopes at the HLA-A, -B,
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STUDY obJeCTIveS aND aNaLYSeS
The primary objective of the study was to predict dn-DSA formation by HLA immunogenicity. The secondary objectives were to characterize dn-DSA in this setting and to assess their impact on clinical outcomes such as ACR, antibody-mediated rejection (AMR), and graft loss.
Categorical variables were compared using chisquared or Fisher's exact test, as appropriate. MedCalc Statistical Software, version 12.7.8 (MedCalc Software, Ostend, Belgium) was used for logistic regression analysis. Multivariate analysis was used to determine correlations and covariance between the variables (program STAGRAPHICS centurion, version XVI; StatPoint Technologies, Inc., Warrenton, VA).
results
Demographic and immunologic characteristics of the patient population, with posttransplant outcomes stratified by formation of dn-DSA, are shown in Tables 1  and 2 , respectively. Demographic variables including primary diagnosis of immune-mediated diseases were comparable between patients with and without dn-DSA formation. Patients' age and race were also comparable between the 2 compared groups.
CM STaTUS, HLa, aND epLeT MM
At the time of transplant, FCCM was positive in 9 of 80 (11%) patients. A significantly higher proportion of patients with dn-DSA had a positive CM. This was true for B cell CM (22% versus 6%; P = 0.03) but not for T cell CM (11% versus 6%; P = 0.38). Degrees of total HLA MM as well as HLA-A, -B, -DR, and -ABDR MM were also comparable between the groups with and without dn-DSA. The total number of class I eplet MMs was comparable between the groups. However, the number of class II eplet MMs was significantly higher in patients developing dn-DSA (38 ± 2.7 versus 28 ± 2.3; P = 0.01). When AbVer eplet MM was compared, there were significantly higher AbVer class II eplet MMs in patients developing dn-DSA (14 ± 1.1 versus 10 ± 1; P = 0.02).
proSpeCTIve DSa MoNITorING aND dn-DSa ForMaTIoN
Dn-DSAs appeared at median 165 (9-906) days after transplantation. Class I dn-DSAs were identified in 5 (18%) patients, and class II dn-DSAs were identified in 22 (82%) patients. The posttransplant course of dn-DSA formation is shown in Fig. 1 . NOTE: Degree of HLA MMs for -A, -B, and -DR (0, 1, and 2) and for -ABDR (2-6) are shown in percentages. Data are given as n (%) or mean ± standard deviation.
IMMUNoGeNeCITY oF epLeT MM aND preDICTIoN oF DN-DSa ForMaTIoN
To identify predictors of dn-DSA formation, a multivariate logistic regression analysis was performed, which included variables such as number of total HLA MMs, number of DR/DQ HLA MMs, number of DR/DQ eplet MMs, recipient age, and primary disease. The number of DR/DQ MM eplets was strongly associated with the risk of developing de novo DR/DQ DSAs (odds ratio [OR], 1.2; 95% CI; P < 0.01; Fig.  2 ). The total number of AbVer DQ (A/B) locus MM eplets also appeared to be a predictor of DSA development. The probability of de novo class II DSA development was higher when the number of total AbVer MM eplets was more than 12 ( 
CLINICaL oUTCoMeS
At a median follow-up of 6.8 years, there were 2 graft losses due to HCV recurrence. Ten patients with functioning liver grafts died. None of the graft losses were a result of chronic rejection. Graft loss was not significantly influenced by the presence of dn-DSA (Fig. 5 ). In 16 of 27 patients with dn-DSA, 53 liver allograft biopsies were performed at a median 19 (4-66) months during posttransplant course. Chronic rejection was not found in any of the biopsies. ACR was diagnosed in 4 of 27 patients with dn-DSA. There was no association between ACR and dn-DSAs. In 5 of 9 patients with ACR, there were no dn-DSAs. Timing of ACR did not coincide with the formation of dnDSAs, which were already present in these patients for some time. Additionally, there were no elevations in the MFIs of dn-DSA at the time of ACR during the posttransplant course. ACR was, however, associated with a higher number of class I eplet MM (mean eplet MM in patients with ACR was 20 ± 1.3 versus 14 ± 1 in patients without ACR; P < 0.01). This was true even when only AbVer class I eplet MMs were considered. Median AbVer eplet MM in patients with ACR was 11 ± 1.1 versus 7 ± 0.6 in patients without ACR; P = 0.02. When HLA ABDR MM, FCCM, dn-DSA formation, class I and class II eplet MMs were entered as variables in multivariate regression analysis, class I eplet MM was a risk factor for ACR (hazard ratio, 1.6; 95% confidence interval [CI], 1.1-2.3; P = 0.02).
Protocol biopsies were performed only in patients with HCV as the primary diagnosis. Dn-DSAs were identified in 10 patients with HCV cirrhosis. Protocol biopsies from these patients revealed HCV recurrence with the progression of fibrosis in 6 patients. 
Discussion
To the best of our knowledge, this is the first study to report the impact of HLA epitope/eplet MM on dn-DSA formation in LT in a setting of prospective DSA monitoring. In this study, we demonstrated that the total number of eplet MM, as well as the number of AbVer eplet MMs, are strong predictors of dn-DSA formation. Its predictive ability was better than class I, class II, or combined HLA antigen MM. Several studies have previously demonstrated this observation in kidney transplant recipients. Wiebe and Nickerson recently reported that donor-recipient HLA MM at the amino acid level serve as potential epitopes for dn-DSA development and correlate with late kidney rejection and kidney allograft loss. (20) In another prospective monitoring study of kidney transplant recipients, the number of locus-specific eplet MMs was highly predictive of HLA-DR and HLA-DQ dn-DSA development. (21) In their study, the eplet MM threshold of 10 for HLA-DR and 17 for HLA-DQ were identified to predict the risk of dn-DSA development after a Log-rank P < 0.01 median follow-up of 6.9 years. Similarly, in our study, a threshold of 12 was found to be predictive of dn-DSA formation. In our study, an association between class I eplet MM and ACR was an observational finding. A majority of the published literature has focused on class II eplet MMs because of the interest in DSA-mediated graft injury, and DQB1 eplet MMs have been considered particularly immunogenic. (21, 22) Original article | 1107 the likelihood of class I DSA at the time of kidney allograft failure. (23) In a single-center study of 101 kidney transplant recipients, transplant recipients with >10 class I triplet MMs experienced an increased risk of graft loss in excess of 5 times compared with those with 10 or fewer class I triplet MMs. (24) We did not observe any associations between dn-DSA development and clinical outcomes such as ACR or graft loss, and none of the recipients developed acute or chronic AMR. These observations may be attributed to the potent induction immunosuppression we used. With the use of induction immunosuppression composed of antithymocyte globulin and rituximab, we have noticed lower overall rejection rates in our patient population, even in the setting of positive CM transplants. (25, 26) There may have been subtle changes within the allografts that were not captured due to the lack of protocol biopsies. Thus, we cannot strongly recommend intensifying surveillance and increasing immunosuppression for patients with a higher degree of epitope MM in our cohort. However, transplant professionals who routinely augment immunosuppression in patients with dn-DSAs may use this approach to identify dn-DSAs preemptively with closer surveillance in donor-recipient pairs with higher epitope MMs.
Another potential opportunity to exploit this stratification is in immunosuppression minimization trials, particularly in LT. A randomized controlled trial of tacrolimus withdrawal in low-risk kidney transplant patients was stopped early because of the development of rejection and dn-DSAs in the tacrolimus withdrawal arm. (27) Further analysis found that all patients with HLA-DQ dn-DSAs had HLA-DQ eplet MM loads above the threshold defined previously, suggesting that class II eplet load at the time of transplant may serve as an important patient selection criterion. In this study, a stable clinical course on adequate immunosuppression failed to predict risk. There is no additional cost for epitiope matching because the information required is routinely obtained during HLA typing. However, the utility of epitope matching may be limited in a select group of immunogenic recipients or those for immunosuppressive minimization trials.
There are some weaknesses of our study. Protocol biopsies were performed only in 21 HCV patients, of whom 6 patients developed DSAs. Although protocol biopsies would have demonstrated subclinical pathologic changes in the liver allografts, the main objective of this study was to evaluate the impact of HLA epitope MM on DSA formation and not to evaluate clinicopathologic impact of dn-DSA. Also, several studies have been published in this area without protocol biopsies. (9, 13, 16) On the other hand, if this approach were to be used in immunosuppression minimization, protocol biopsies would be necessary. A second weakness of our study is that our study population did not have any events of AMR and chronic rejection. However, the strength of this study is in the prospective nature of DSA monitoring in a homogeneous patient population. We believe these observations are important because other investigators have shown the clinical significance of dn-DSAs. (4, 6, 7) In conclusion, understanding eplet MM in LT may stratify immunologic risk. Patients with low eplet MM loads or without highly immunogenic epitope MMs could be considered low-risk candidates for immunosuppressive minimization. These strategies will require testing in prospective trials to validate the hypotheses.
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